Deutsche Bank AG Buys New Shares in Waters Corporation $WAT

by · The Cerbat Gem

Deutsche Bank AG bought a new position in shares of Waters Corporation (NYSE:WAT – Free Report) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 416,850 shares of the medical instruments supplier’s stock, valued at approximately $156,335,000.

A number of other hedge funds have also recently added to or reduced their stakes in WAT. California Public Employees Retirement System grew its holdings in Waters by 25.4% in the first quarter. California Public Employees Retirement System now owns 138,423 shares of the medical instruments supplier’s stock valued at $41,222,000 after purchasing an additional 28,074 shares during the period. Banque Cantonale Vaudoise raised its stake in Waters by 329.0% during the fourth quarter. Banque Cantonale Vaudoise now owns 4,294 shares of the medical instruments supplier’s stock worth $1,631,000 after purchasing an additional 3,293 shares during the period. Ramsay Stattman Vela & Price Inc. purchased a new position in Waters during the first quarter worth approximately $942,000. Dudley & Shanley Inc. boosted its holdings in shares of Waters by 101.3% in the 2nd quarter. Dudley & Shanley Inc. now owns 23,590 shares of the medical instruments supplier’s stock valued at $8,847,000 after purchasing an additional 11,870 shares during the last quarter. Finally, Rockefeller Capital Management L.P. boosted its holdings in shares of Waters by 106.7% in the 4th quarter. Rockefeller Capital Management L.P. now owns 2,751 shares of the medical instruments supplier’s stock valued at $1,045,000 after purchasing an additional 1,420 shares during the last quarter. 94.01% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, Director Christopher A. Kuebler sold 3,626 shares of the stock in a transaction that occurred on Thursday, August 6th. The stock was sold at an average price of $397.94, for a total transaction of $1,442,930.44. Following the completion of the transaction, the director directly owned 17,808 shares in the company, valued at approximately $7,086,515.52. This represents a 16.92% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 0.31% of the stock is currently owned by insiders.

Waters Trading Up 3.8%

NYSE:WAT opened at $416.45 on Thursday. The business’s 50-day moving average is $379.73 and its two-hundred day moving average is $346.54. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.86 and a quick ratio of 1.29. Waters Corporation has a 12 month low of $282.77 and a 12 month high of $420.26. The firm has a market capitalization of $40.92 billion, a PE ratio of 103.85, a price-to-earnings-growth ratio of 2.33 and a beta of 1.19.

Waters (NYSE:WAT – Get Free Report) last released its quarterly earnings results on Tuesday, August 4th. The medical instruments supplier reported $3.05 earnings per share for the quarter, topping analysts’ consensus estimates of $3.01 by $0.04. The firm had revenue of $1.65 billion during the quarter, compared to analysts’ expectations of $1.62 billion. Waters had a return on equity of 11.27% and a net margin of 3.58%.Waters’s quarterly revenue was up 113.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.95 EPS. Waters has set its Q3 2026 guidance at 3.950-4.050 EPS and its FY 2026 guidance at 14.450-14.650 EPS. Research analysts predict that Waters Corporation will post 14.57 earnings per share for the current fiscal year.

Analyst Ratings Changes

WAT has been the subject of a number of research analyst reports. Morgan Stanley set a $430.00 price objective on Waters in a report on Wednesday, August 5th. Wall Street Zen cut Waters from a “buy” rating to a “hold” rating in a report on Monday, July 20th. Bank of America boosted their price target on Waters from $370.00 to $400.00 and gave the company a “neutral” rating in a research report on Tuesday, June 2nd. Royal Bank Of Canada upped their price target on Waters from $435.00 to $475.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 5th. Finally, UBS Group raised their price objective on Waters from $330.00 to $375.00 and gave the stock a “neutral” rating in a report on Wednesday, May 6th. Three research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and eight have assigned a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $420.35.

Get Our Latest Stock Analysis on Waters

Waters Company Profile

(Free Report)

Waters Corporation is a global provider of analytical instruments, software and services for laboratory and research applications. The company designs, manufactures and sells technologies centered on liquid chromatography, mass spectrometry, separation science, and related sample preparation and detection systems. Its product portfolio includes chromatographs, mass spectrometers, columns and consumables, laboratory informatics and workflow software, as well as technical support and training services that help customers run and interpret complex analyses.

Waters serves a wide range of end markets that include pharmaceutical and biotechnology companies, contract research and testing laboratories, academic and government research institutions, clinical diagnostics, food and environmental testing, and industrial and chemical manufacturers.

Recommended Stories

Want to see what other hedge funds are holding WAT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Waters Corporation (NYSE:WAT – Free Report).